Imaging Studies and the Development of Multiple Myeloma
Status:
Withdrawn
Trial end date:
2014-04-23
Target enrollment:
Participant gender:
Summary
Background:
- Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells,
which help produce antibodies and fight infection. MM is nearly always preceded by a
pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS) or smoldering
multiple myeloma (SMM). Currently, it is not possible to predict when someone with MGUS or
SMM will develop MM. Also, the disease changes in those early states are not well understood.
Researchers want to look at imaging studies of people with MGUS, SMM, and MM. They will study
whether the growth of blood vessels can be used to predict disease progression.
Objectives:
- To use imaging studies to evaluate disease progression in multiple myeloma.
Eligibility:
- Individuals at least 18 years of age who have MGUS, SMM, or newly diagnosed MM.
Design:
- Participants will be screened with a physical exam and medical history. They will also
have blood and urine tests, and provide bone marrow samples.
- Participants will have positron emission tomography (PET) scans with the new contrast
agent [18]F-Fluciclatide. The contrast agent is intended to show patterns of increased
vessel growth in the bone marrow.
- Participants will also have a magnetic resonance imaging (MRI) scan. This scan will be
done according to standard procedures.
- Researchers will compare these scans with blood tests and other clinical information to
study disease progression of MGUS, SMM, and MM.